Extracorporeal Photopheresis: Scientific and Technical Considerations for Improving Clinical Management of PatientsFrédéric Garban1-4*, Caroline Makowski2, Sylvain Carras2, Philippe Drillat2, Remy Gressin1, Jean Yves Cahn1,3,4 and David Laurin2,3
- *Corresponding Author:
- Prof. Fréderic Garban
Établissement Français du Sang Rhône Alpes
29 avenue maquis du Grésivaudan
F38700 La Tronche, France
E-mail: [email protected]
Received date: July 07, 2014; Accepted date: September 09, 2014; Published date: September 11, 2014
Citation: Garban F, Makowski C, Carras S, Drillat P, Gressin R, et al. (2014) Extracorporeal Photopheresis: Scientific and Technical Considerations for Improving Clinical Management of Patients. J Stem Cell Res Ther 4:232. doi:10.4172/2157-7633.1000232
Copyright: © 2014 Garban F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Extracorporeal photopheresis or chemophototherapy (ECP) is a current therapy and concept that has demonstrated clinical efficacy in the treatment of acute and chronic graft versus host disease (GVHD), Sezary syndrome or cutaneous T-cell lymphoma (CTCL) and organ transplant rejection. Patient inclusion in ECP protocols increases due to the diffusion of technical progress but has to be explored regarding various schedules and processes. ECP mechanisms of action are still unclear despite evident implication of a complex cascade beginning from the apoptosis of the various cell types collected and exposed to the process that is followed by an immunomodulation via antigen presentation. Exploration of the mechanisms in animal models has many limits that weakness human clinical link. Beside major indications, the barrier to ECP treatment extension is the absence of randomized trials in comparison to alternative therapies. The cost of ECP treatment is also a limitation and has to be evaluated relative to other strategies. Nevertheless, the efficacy and the absence of major side effects deserve attention, mainly for the extension of the ECP treatment in clinical trials as new therapeutic line.